Insys Therapeutics, Inc. (NASDAQ:INSY)’s shares have been under pressure recently on news regarding prescribing patterns for Subsys. The stock price of the company tumbled 17.41% and 15.45% in the last two consecutive trading sessions. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was -15.70% in last session and finished the day at $23.01. Traded volume was 3.24million shares in the last session and the average volume of the stock remained 547.74K shares. The beta of the stock remained 1.51. Insys Therapeutics Inc (NASDAQ:INSY) insider ownership is 0.50%.

Ingredients and medical food company, Enzymotec Ltd (NASDAQ: ENZY), is plummeting in the market by a high of 28.57% after the company reported its first quarter unaudited financial results. During the quarter, the company signed a settlement and license agreement with Neptune Technologies & Bio resources. It also completed the repayment of its long-term loan subject to financial and other covenants. Based on consolidation method, net revenues of Enzymotec Ltd (NASDAQ:ENZY) for the quarter increased by 43.5% to $23.7 million up from $16.5 million reported for the same period in 2013. Based on an equity method, revenues should come in at $17.9 million from $13.8 million a year ago, representing a 29.1% increase. Increase in volume sales and higher margin products, as well as the operation, of a new extraction facility enabled the first quarter gross margin improve by 1400 basis points to 61.6%, up from 47.3% a year ago. Enzymotec Ltd (NASDAQ:ENZY) dropped -32.03 percent to $13.75 Wednesday on volume of 2.52million shares. The intra-day range of the stock was $13.60 to $18.46. Enzymotec Ltd (NASDAQ:ENZY) has a market capitalization of $308.90million.

Geron Corporation (NASDAQ:GERN) Director Daniel Bradbury purchased 142,776 shares of the stock in a transaction dated Friday, May 9th. The stock was purchased at an average cost of $1.75 per share, for a total transaction of $249,858.00. Following the completion of the purchase, the director now directly owns 142,776 shares in the company, valued at approximately $249,858. Geron Corporation (NASDAQ:GERN)’s stock on May 14, 2014 reported a decrease of -6.44% to the closing price of $1.89. Its fifty two weeks range is $1.05 -$7.79. The total market capitalization recorded $296.61million. The overall volume in the last trading session was 2.22million shares. In its share capital, GERN has 156.94million outstanding shares.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported its 1Q14 earnings for the quarter ended March 31, 2014. The company reported wider net loss for 1Q14 at $16.1 million ($0.17 per share) as compared to a net loss of $11.7 million ($0.14 per share) for 1Q13. The company reported cash equivalents, marketable securities and interest receivable at $144.7 million as at March 31, 2014. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported research and development expenses for 1Q14 at $12.8 million against $8.7 million for 1Q13. The increase in R&D expenses was largely attributed to higher pre-clinical as well as manufacturing costs for ACH-3422 and higher clinical development costs for ACH-2684 and ACH-3102. On Wednesday, shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) dropped -6.57% to close the day at $2.70. Company return on investment (ROI) is % and its monthly performance is recorded as -1.46%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) quarterly revenue growth is -26.23%.